Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Purchased by Graham Capital Management L.P.

Graham Capital Management L.P. grew its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 165.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 41,676 shares of the company's stock after buying an additional 26,000 shares during the period. Graham Capital Management L.P. owned 0.15% of Castle Biosciences worth $1,111,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Castle Biosciences by 4.8% during the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock worth $48,837,000 after purchasing an additional 83,783 shares during the period. Dimensional Fund Advisors LP boosted its position in Castle Biosciences by 15.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 999,466 shares of the company's stock worth $26,636,000 after purchasing an additional 134,645 shares during the period. Wellington Management Group LLP purchased a new stake in Castle Biosciences during the 4th quarter worth $19,244,000. Renaissance Technologies LLC boosted its position in Castle Biosciences by 39.9% during the 4th quarter. Renaissance Technologies LLC now owns 685,000 shares of the company's stock worth $18,255,000 after purchasing an additional 195,438 shares during the period. Finally, Geode Capital Management LLC boosted its position in Castle Biosciences by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 628,196 shares of the company's stock worth $16,746,000 after purchasing an additional 3,513 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CSTL has been the subject of a number of research reports. Robert W. Baird upped their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a "buy" rating in a research report on Friday, March 28th. Lake Street Capital decreased their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group decreased their price target on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $37.50.

Insider Activity

In related news, insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $20.12, for a total transaction of $455,496.68. Following the sale, the insider now owns 80,465 shares in the company, valued at $1,618,955.80. This represents a 21.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 27,454 shares of company stock worth $553,030. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Stock Up 1.6%

Shares of Castle Biosciences stock traded up $0.27 during trading on Friday, reaching $16.75. The company had a trading volume of 393,888 shares, compared to its average volume of 405,415. The company has a market cap of $483.61 million, a price-to-earnings ratio of 83.75 and a beta of 1.19. The firm's fifty day moving average is $19.49 and its 200-day moving average is $25.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a fifty-two week low of $15.70 and a fifty-two week high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). The company had revenue of $87.99 million during the quarter, compared to analyst estimates of $80.40 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. On average, analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.